0000000000455620

AUTHOR

Thomas R. Kreil

showing 2 related works from this author

Impact of vCJD on blood supply.

2007

Variant Creutzfeldt-Jakob disease (vCJD) is an at present inevitably lethal neurodegenerative disease which can only be diagnosed definitely post mortem. The majority of the approximately 200 victims to date have resided in the UK where most contaminated beef materials entered the food chain. Three cases in the UK demonstrated that vCJD can be transmitted by blood transfusion. Since BSE and vCJD have spread to several countries outside the UK, it appears advisable that specific risk assessments be carried out in different countries and geographic areas. This review explains the approach adopted by Germany in assessing the risk and considering precautionary measures. A fundamental premise is…

medicine.medical_specialtyBlood transfusionBovine spongiform encephalopathymedicine.medical_treatmentSpecific riskBioengineeringBlood Component TransfusionBlood DonorsDiseaseApplied Microbiology and BiotechnologyCreutzfeldt-Jakob SyndromeBlood Component TransfusionEnvironmental healthGermanymental disordersmedicineBlood-Borne PathogensAnimalsHumansLeukapheresisPharmacologyGeneral Immunology and Microbiologybusiness.industryIncidencePatient SelectionTransfusion ReactionGeneral MedicineRuminantsmedicine.diseasenervous system diseasesSurgeryEncephalopathy Bovine SpongiformPopulation dataBlood supplyCattleRisk assessmentbusinessBiotechnologyBiologicals : journal of the International Association of Biological Standardization
researchProduct

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population

2013

BACKGROUND: Children are highly vulnerable to infection with novel influenza viruses. It is essential to develop candidate pandemic influenza vaccines that are safe and effective in the pediatric population. METHODS: Infants and children aged 6-35 months and 3-8 years, respectively, were randomized to receive 2 immunizations with a 7.5-µg or 3.75-µg hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years received a 7.5-µg dose only. A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later. HA and neuraminidase antibody responses were assessed. RESULTS: Vaccination was safe and we…

H5N1 vaccinebiologybusiness.industryImmunogenicityvirus diseasesmedicine.disease_causeVirologyInfluenza A virus subtype H5N1VaccinationInfectious DiseasesImmunizationPandemicmedicinebiology.proteinImmunology and AllergybusinessNeuraminidaseHeterosubtypic immunityJournal of Infectious Diseases
researchProduct